Maze Therapeutics

Business person contemplating how to navigate a maze made of money
Biotech

Maze finds its way to $115M series D

Maze will use the raise to advance its lead assets, MZE829 and MZE782, in different kidney disease indications.
Darren Incorvaia Dec 3, 2024 12:42pm
Graphic of two hands shaking under a red and purple light

After FTC stalled Sanofi deal, Shionogi bags Maze's Pompe drug

May 10, 2024 5:02am
Graphic image of the words try again on a purple background with some pixelated art below

Sanofi CEO does not rule out future Pompe BD despite FTC moves

Jan 10, 2024 3:37pm
end of the road road block shut down closed blocked

Sanofi scraps Maze deal after FTC throws up antitrust obstacles

Dec 12, 2023 6:00am
Graphic image of a red ball navigating a maze

Sanofi to enter Maze deal with $750M pact for Pompe med

May 1, 2023 6:00am
CL paragliding mountain

BIO CEO out the door—Chutes & Ladders

Oct 14, 2022 9:30am